Nesseem D I, Michel C G, Sleem A A, El-Alfy T S
Pharmaceutics Department, National Organization for Drug Control & Research (NODCAR), 6 Abou Hazem St. Pyramids Ave, Cairo, Egypt.
Pharmazie. 2009 Feb;64(2):104-9.
This study deals with the formulation of antihyperglycemic leaf extracts of Zizyphus spina-christi (L.) Willd. A bioactivity guided fractionation of different leaf extracts [defatted ethanol 70% (a), butanol (b), ethanol 70% (c), ethyl acetate (d) and petroleum ether (e) extracts] revealed that extract (c) possessed the highest antihyperglycemic activity followed by (b) and (a). HPLC was adopted for standardization of the extract (c) based on evaluation of the major saponin christinin-A which was used as marker. The detection limit was 9.45 mg/ml for Christinin-A. Extracts (a), (b) and (c) were separately formulated in soft (S) and hard (H) gelatin capsules. Two different formulations (F1 and F2) were tried using different excipients suitable for oral drug delivery. Formula 1, used for soft gelatin capsules [(F1) Sa, Sb, Sc] Formula 2, used for hard gelatin capsules [(F2) - Ha, Hb, Hc]. The recovery rates of the samples of saponin were in the range 99.43-101.86% at 200, 800 microg/ml and 1200 microg/ml. Saponin release rates from different formulae were carried out using dissolution tester USP XXIV. The highest release was obtained from formulation Sc. The release of the extracts followed diffusion mechanism. The selected formula Sc exhibited highest anti-diabetic activity (P < 0.01) on acute and long-term administration and highest saponin release. This formula (Sc) contained poly-oxyethylene (20) cetyl ether (BC-20TX), PEG 400, PEG 6000, purified water, meglyol 810, ascorbic acid and 200 mg of extract (c).
本研究涉及枣(Zizyphus spina-christi (L.) Willd.)叶抗高血糖提取物的制剂。对不同叶提取物[脱脂70%乙醇提取物(a)、丁醇提取物(b)、70%乙醇提取物(c)、乙酸乙酯提取物(d)和石油醚提取物(e)]进行生物活性导向分级分离,结果显示提取物(c)具有最高的抗高血糖活性,其次是提取物(b)和(a)。基于对用作标志物的主要皂苷枣皂苷-A的评估,采用高效液相色谱法对提取物(c)进行标准化。枣皂苷-A的检测限为9.45 mg/ml。提取物(a)、(b)和(c)分别制成软胶囊(S)和硬胶囊(H)。使用适合口服给药的不同辅料尝试了两种不同的制剂(F1和F2)。配方1,用于软胶囊[(F1)Sa、Sb、Sc];配方2,用于硬胶囊[(F2)- Ha、Hb、Hc]。皂苷样品在200、800 μg/ml和1200 μg/ml时的回收率在99.43 - 101.86%范围内。使用美国药典XXIV溶出度测试仪测定不同配方中皂苷的释放速率。制剂Sc的释放率最高。提取物的释放遵循扩散机制。所选配方Sc在急性和长期给药时表现出最高的抗糖尿病活性(P < 0.01)和最高的皂苷释放率。该配方(Sc)含有聚氧乙烯(20)十六烷基醚(BC - 20TX)、聚乙二醇400、聚乙二醇6000、纯化水、聚甘油810、抗坏血酸和200 mg提取物(c)。